• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?

作者信息

Angelis Aris, Aggarwal Ajay, Miners Alec, Grieve Richard, Cairns John, Briggs Andrew

机构信息

Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, WC1H 9SH, UK.

Department of Health Policy and LSE Health, London School of Economics and Political Science, London, WC2A 2AE, UK.

出版信息

J R Soc Med. 2023 Oct;116(10):324-330. doi: 10.1177/01410768231192476. Epub 2023 Aug 24.

DOI:10.1177/01410768231192476
PMID:37619606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10695148/
Abstract
摘要

相似文献

1
The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?创新药物基金：是实现更快、更公平获取新的有前景药物的通用模式，还是低价值蔓延的特洛伊木马？
J R Soc Med. 2023 Oct;116(10):324-330. doi: 10.1177/01410768231192476. Epub 2023 Aug 24.
2
Enhancing global access to cancer medicines.加强全球获取癌症药物的机会。
CA Cancer J Clin. 2020 Mar;70(2):105-124. doi: 10.3322/caac.21597. Epub 2020 Feb 18.
3
Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake.透过澳大利亚参议院调查视角看高成本癌症药物的获取——界定利益相关的“商品”
J Bioeth Inq. 2017 Sep;14(3):401-410. doi: 10.1007/s11673-017-9800-2. Epub 2017 Jul 18.
4
Accessibility crisis of essential medicines at Sudanese primary healthcare facilities: a cross-sectional drugs' dispensaries assessment and patients' perspectives.苏丹基层医疗保健机构基本药物可及性危机：横断面药物配给评估和患者视角。
Int J Equity Health. 2023 Oct 17;22(1):216. doi: 10.1186/s12939-023-02009-y.
5
Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis.通过印度健康影响基金改善药品可及性：利益相关者分析
Glob Health Action. 2018;11(1):1434935. doi: 10.1080/16549716.2018.1434935.
6
Access to medicines through health systems in low- and middle-income countries.中低收入国家通过卫生系统获得药品。
Health Policy Plan. 2019 Dec 1;34(Supplement_3):iii1-iii3. doi: 10.1093/heapol/czz119.
7
A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.美国、英国、澳大利亚和新西兰的单一支付方制度下，许可和补贴药品获取的三维视图。
Pharmacoeconomics. 2012 Nov 1;30(11):1051-65. doi: 10.2165/11595270-000000000-00000.
8
Noncommunicable diseases, access to essential medicines and universal health coverage.非传染性疾病、基本药物获取和全民健康覆盖。
Glob Health Action. 2019;12(1):1670014. doi: 10.1080/16549716.2019.1670014.
9
Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.患者尽早获得药物：卫生技术评估机构需要跟上新的上市许可方法。
Public Health Genomics. 2016;19(3):187-91. doi: 10.1159/000446537. Epub 2016 Jun 1.
10
Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?非洲的药品获取与丙型肝炎：分级定价和自愿许可能否确保普遍获取、健康公平与公正？
Global Health. 2017 Sep 13;13(1):73. doi: 10.1186/s12992-017-0297-6.

引用本文的文献

1
Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review.澳大利亚、新加坡、韩国、英国和美国国家罕见病资助政策的比较政策分析：一项范围综述
Health Econ Rev. 2024 Jun 19;14(1):42. doi: 10.1186/s13561-024-00519-1.
2
Rigour and science in drug regulatory approval.药品监管审批中的严谨性与科学性。
J R Soc Med. 2023 Oct;116(10):323. doi: 10.1177/01410768231211565.